Recreational Use, Analysis and Toxicity of Tryptamines

Total Page:16

File Type:pdf, Size:1020Kb

Recreational Use, Analysis and Toxicity of Tryptamines Send Orders for Reprints to [email protected] 26 Current Neuropharmacology, 2015, 13, 26-46 Recreational Use, Analysis and Toxicity of Tryptamines Roberta Tittarelli1, Giulio Mannocchi1, Flaminia Pantano1 and Francesco Saverio Romolo1,2,* 1Legal Medicine Section, Department of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, “Sapienza” University of Rome, Viale Regina Elena, 336, 00161 Rome, Italy; 2Institut de Police Scientifique, Université de Lausanne, Batochime, 1015 Lausanne, Switzerland Abstract: The definition New psychoactive substances (NPS) refers to emerging drugs whose chemical structures are similar to other psychoactive compounds but not identical, representing a “legal” alternative to internationally controlled drugs. There are many categories of NPS, such as synthetic cannabinoids, synthetic cathinones, phenylethylamines, piperazines, ketamine derivatives and tryptamines. Tryptamines are naturally occurring compounds, which can derive from the amino acid tryptophan by several biosynthetic pathways: their structure is a combination of a benzene ring Roberta Tittarelli and a pyrrole ring, with the addition of a 2-carbon side chain. Tryptamines include serotonin and melatonin as well as other compounds known for their hallucinogenic properties, such as psilocybin in ‘Magic mushrooms’ and dimethyltryptamine (DMT) in Ayahuasca brews. Aim: To review the scientific literature regarding tryptamines and their derivatives, providing a summary of all the available information about the structure of these compounds, their effects in relationship with the routes of administration, their pharmacology and toxicity, including articles reporting cases of death related to intake of these substances. Methods: A comprehensive review of the published scientific literature was performed, using also non peer-reviewed information sources, such as books, government publications and drug user web fora. Conclusions: Information from Internet and from published scientific literature, organized in the way we proposed in this review, provides an effective tool for specialists facing the emerging NPS threat to public health and public security, including the personnel working in Emergency Department. Keywords: Clinical effects, Emergency Departments, Fatalities, Forensic Toxicology, Intoxication, New Psychoactive Substances (NPS), Tryptamines. INTRODUCTION regards the Internet “as a growing source of on-line drug trafficking”: products purchased on Internet may vary over The New psychoactive substances (NPS) are defined by time proposing chemicals always different, not listed in European Community (2005) as “substances of abuse either literature, meaning that users are often unaware of what or in a pure form or preparation that are not controlled by the 1961 Single Convention on Narcotics Drugs or the 1971 how much they are taking [4], causing increasing risks to Convention on Psychotropic Substances, but which may public health. The phenomenon of marketing illicit drug pose a public health threat comparable to scheduled ‘‘derivatives’’ grew mainly because of their easy availability substances” [1]. According to Zuba, “they are created on the Internet or in “head shops”. The use of NPS has usually by manipulating already existing psychoactive increased dramatically in recent years: only in the European substances or, less, by finding drugs with a new chemical Union, the number of NPS identified has risen “from 14 at structure that may produce similar effects to those of the the end of 2005 to 236 by the end of 2012” [5]. The majority of illegal drugs of abuse” [2]. They may be formulated as new recreational synthetic drugs fall into one of the following “bulk powders, liquids, tablets, capsules, blotters,” or herbal psychoactive drug categories: synthetic cannabinoids, synthetic preparations, indeed on the web sites these drugs are sold as cathinones, phenylethylamines, piperazines, ketamine “research chemicals,” “incense,” “bath salts,” or “plant- derivatives and tryptamines. growth fertilizers,” equipped with labels specifying that the Tryptamines are a group of monoamine alkaloids (Fig. 1), products are “not for human consumption” or “not for sale to which can be synthesized by decarboxylation of the minors” [3]. The International Narcotics Control Board aminoacid tryptophan: they can be found in plants, fungi, animals, microbes and amphibia [6]. *Address correspondence to this author at the Legal Medicine Section, Tryptamines have an indole ring structure, a fused double Department of Anatomical, Histological, Forensic Medicine and Orthopedic ring comprising of a pyrrole ring and a benzene ring, joined Sciences, “Sapienza” University of Rome, Viale Regina Elena, 336, 00161 Rome, Italy; Tel: 00390649912581; Fax: 00390649912614; to an amino group by 2 carbon side chain. E-mail: [email protected] 1570-159X/15 $58.00+.00 ©2015 Bentham Science Publishers Recreational Use, Analysis and Toxicity of Tryptamines Current Neuropharmacology, 2015, Vol. 13, No. 1 27 Fig. (1). Tryptamine structure. The tryptamines play a fundamental role in human life: serotonin (5-hydroxytryptamine, 5-HT), one of the most important signaling hormones [7] in the body, is a tryptamine natural derivative involved in regulation and modulation of multiple processes within the central nervous system, such as sleep, cognition, memory, temperature regulation and behavior [8]. Moreover, mammalian brain contains very low concentrations (in the low ng/g range) of tryptamine, which may act as a neurotransmitter or modulator Fig. (3). Tryptamine structure as template for new psychoactive [9]: it acts as a serotonin releasing agent and it is an enhancer compounds. of serotonergic activity [10]. Gibbons in his publication, defines the nature “an astounding chemist (..) able to produce α-methyltryptamine (5-MeO-AMT)], being the presence of compounds that have profound effects on the central nervous an alpha carbon methyl group, a characteristic in common system (CNS)”[11]. Naturally occurring derivatives of the with amphetamine [14, 18]. The synthesis and the effects of tryptamines are present in the ‘Magic mushrooms’ belonging to Psilocybe cubensis species, which contain psilocybin these compounds have been fully investigated by Alexander T. Shulgin who described his experiences within the book (4-phosphoryloxy-N,N-dimethyltryptamine) and psilocin Tihkal [19]: he identified 55 molecules and he tested these (4-hydroxy-N,N-dimethyltryptamine), the latter showing substances on volunteers to assess their effects according to marked similarities with serotonin (Fig. 2). his rating scale. Recreational use of tryptamines requires Another example of the ability of the natural world to only minute amounts to produce psychotropic phenomena create hallucinogenic substances, is the 5-hydroxy-N,N- and has been associated to intoxications and fatalities for dimethyltryptamine (bufotenine), a positional isomer of several reasons, including low toxic concentrations. Moreover, psilocin [12], which is contained in the skin and glands of these molecules are not routinary detected with common various species of toad of the genus Bufo [13]. Chemical screening panels, so far in emergency rooms the test could modifications of the nucleus structure of the tryptamine result completely negative leading to misunderstanding molecule produce new compounds which may cause diagnosis or therapy and limited evaluation of the phenomenon. alterations of the physical and mental status: substitutions on It is very important to organize the information pertaining to the indole ring, on the two carbons of the side chain and these substances to provide a tool for specialists facing this alkylation of the side-chain nitrogen result in new emerging threat to public health and public security. For this neuroactive compounds, ranging from toxic substances to reason a comprehensive review of the scientific literature anti-migraine drugs, such as Sumatriptan [14], Rizatriptan and internet sites regarding tryptamines and their derivatives and Zolmitriptan (Fig. 3). was carried out, providing a summary of all the available information about the structure of these compounds, their Tryptamines show agonist action at multiple receptors, effects in relationship with the routes of administration including 5HT2a-1a-2c [15] serotonin receptors [16], and and their toxicity, including articles reporting cases of several ion channels [17]. In general, tryptamines seem to death related to intake of these substances and analytical have hallucinogenic properties, rather than stimulant or methods for the determination and quantification of some entactogenic characteristics: their alpha methylation leads to tryptamines. stimulant activity [α-methyltryptamine (AMT), 5-methoxy- CLASSIFICATION OF TRYPTAMINES BASED ON THEIR CHEMICAL STRUCTURES Several classifications have been suggested for these substances. Nichols classified tryptamines in two main groups: -the simple tryptamines, including dimethyltryptamine (DMT), and the ergolines (a group of chemical compounds that were originally synthesized from a fungus ergot, among which is the lysergic acid diethylamide (LSD). Fantegrossi divided tryptamines in three subgroups: (1) simple tryptamines, without modification of the indole ring; (2) tryptamines having a modification on the 4-position on the indole ring; Fig. (2). Psilocin and serotonin structure. (3) tryptamines having a modification on the 5-position. Only 28 Current Neuropharmacology,
Recommended publications
  • S1 Table. List of Species Modeled, Families, Habit and Number of Cleaned Records (NR)
    S1 Table. List of species modeled, families, habit and number of cleaned records (NR). Family Species Habit NR Pinaceae Abies guatemalensis Rehd. Tree 46 Fabaceae Acacia aroma Hook. & Arn. Tree 159 Fabaceae Acacia caven (Molina) Molina Tree 123 Fabaceae Acacia furcatispina Burkart Shrub 35 Fabaceae Acacia praecox Griseb. Tree 75 Euphorbiaceae Acalypha macrostachya Jacq. Tree 459 Arecaceae Acrocomia aculeata (Jacq.) Lodd. ex Mart. Palm 166 Fabaceae Adesmia volckmannii Phil. Shrub 63 Arecaceae Allagoptera campestris (Mart.) Kuntze Palm 106 Fabaceae Anadenanthera colubrina (Vell.) Brenan Tree 330 Annonaceae Annona nutans (R.E.Fr.) R.E.Fr. Shrub 64 Loganiaceae Antonia ovata Pohl Tree 113 Araucariaceae Araucaria angustifolia (Bertol.) Kuntze Tree 48 Apocynaceae Aspidosperma quebracho-blanco Schltdl. Tree 83 Arecaceae Astrocaryum murumuru Mart. Palm 66 Anacardiaceae Astronium graveolens Jacq. Tree 282 Amaranthaceae Atriplex canescens (Pursh) Nutt. Shrub 178 Arecaceae Attalea butyracea (Mutis ex L.f.) We Palm 104 Asteraceae Baccharis crispa Spreng. Shrub 142 Asteraceae Baccharis gilliesii A.Gray Shrub 34 Asteraceae Baccharis trimera DC. Shrub 162 Asteraceae Baccharis ulicina Hook. & Arn. Shrub 63 Berberidaceae Berberis microphylla Forst. Shrub 44 Moraceae Brosimum lactescens (S.Moore) C.C.Berg Tree 248 Zygophyllaceae Bulnesia sarmientoi Lorentz ex Griseb. Tree 22 Malpighiaceae Byrsonima coccolobifolia Kunth Shrub 112 Meliaceae Cabralea canjerana (Vell.) Mart. Tree 157 Icacinaceae Calatola costaricensis Standl. Tree 201 Calophyllaceae Calophyllum brasiliense Cambess. Tree 541 Salicaceae Casearia decandra Jacq. Tree 188 Urticaceae Cecropia obtusifolia Bertol. Tree 165 Urticaceae Cecropia pachystachya Trécul Tree 167 Meliaceae Cedrela fissilis Vell. Tree 137 Meliaceae Cedrela odorata L. Tree 436 Malvaceae Ceiba speciosa (A. St.-Hil.) Ravenna Shrub 80 Asteraceae Chuquiraga avellanedae Lorentz Shrub 35 Asteraceae Chuquiraga erinacea D.Don Shrub 75 Fabaceae Copaifera langsdorffii Desf.
    [Show full text]
  • Anaesthesia and Past Use Of
    177 Correspondence were using LSD. It is more popular than other commonly Anaesthesia and past use of used hallucinogens whose quoted incidence of clients are: LSD ketamine 0.1% (super-K/vitamin K.I), psilocybin and psilocin 0.6% (the active alkaloids in the Mexican "magic To the Editor: mushroom"), and 3,4 methylenedioxymethamphetamine We report the case of a 43-yr-old lady who was admitted ~MDMA" 1% (ecstasy). The effects of the concurrent to the Day Surgery Unit for release of her carpal tunnel ingestion of LSD on anaesthesia are well described. 2-4 retinaculum. During the preoperative visit, she reported The long-term effects of the past use of LSD are largely no intercurrent illnesses, drug therapy or allergies. She unknown. We wonder if the hallucinations experienced did say, however, that she was frightened of general anaes- by our patient during anaesthesia were due to her LSD thesia, since she had experienced terrifying dreams during intake many years before. We would be interested to surgery under general anaesthesia on three occasions dur- know if others have had experience anaesthetising patients ing the previous ten years. On further questioning, she who are past users of phencyclidine-derived drugs. admitted that she had used lysergic acid diethylamide (LSD) during the late 1960's, the last occasion being 1968 Geoffrey N. Morris MRCGPFRCA when she had experienced characterstic hallucinations. Patrick T. Magee MSe FRCA She had not experienced hallucinations in the ensuing Anaesthetic Department years, except on the surgical occasions mentioned. Royal United Hospital One of the three previous operations had been per- Combe Park formed at our hospital and the anaesthetic record was Bath BA1 3NG checked.
    [Show full text]
  • Supplementary Materialsupplementary Material
    10.1071/BT13149_AC © CSIRO 2013 Australian Journal of Botany 2013, 61(6), 436–445 SUPPLEMENTARY MATERIAL Comparative dating of Acacia: combining fossils and multiple phylogenies to infer ages of clades with poor fossil records Joseph T. MillerA,E, Daniel J. MurphyB, Simon Y. W. HoC, David J. CantrillB and David SeiglerD ACentre for Australian National Biodiversity Research, CSIRO Plant Industry, GPO Box 1600 Canberra, ACT 2601, Australia. BRoyal Botanic Gardens Melbourne, Birdwood Avenue, South Yarra, Vic. 3141, Australia. CSchool of Biological Sciences, Edgeworth David Building, University of Sydney, Sydney, NSW 2006, Australia. DDepartment of Plant Biology, University of Illinois, Urbana, IL 61801, USA. ECorresponding author. Email: [email protected] Table S1 Materials used in the study Taxon Dataset Genbank Acacia abbreviata Maslin 2 3 JF420287 JF420065 JF420395 KC421289 KC796176 JF420499 Acacia adoxa Pedley 2 3 JF420044 AF523076 AF195716 AF195684; AF195703 Acacia ampliceps Maslin 1 KC421930 EU439994 EU811845 Acacia anceps DC. 2 3 JF420244 JF420350 JF419919 JF420130 JF420456 Acacia aneura F.Muell. ex Benth 2 3 JF420259 JF420036 JF420366 JF419935 JF420146 KF048140 Acacia aneura F.Muell. ex Benth. 1 2 3 JF420293 JF420402 KC421323 JQ248740 JF420505 Acacia baeuerlenii Maiden & R.T.Baker 2 3 JF420229 JQ248866 JF420336 JF419909 JF420115 JF420448 Acacia beckleri Tindale 2 3 JF420260 JF420037 JF420367 JF419936 JF420147 JF420473 Acacia cochlearis (Labill.) H.L.Wendl. 2 3 KC283897 KC200719 JQ943314 AF523156 KC284140 KC957934 Acacia cognata Domin 2 3 JF420246 JF420022 JF420352 JF419921 JF420132 JF420458 Acacia cultriformis A.Cunn. ex G.Don 2 3 JF420278 JF420056 JF420387 KC421263 KC796172 JF420494 Acacia cupularis Domin 2 3 JF420247 JF420023 JF420353 JF419922 JF420133 JF420459 Acacia dealbata Link 2 3 JF420269 JF420378 KC421251 KC955787 JF420485 Acacia dealbata Link 2 3 KC283375 KC200761 JQ942686 KC421315 KC284195 Acacia deanei (R.T.Baker) M.B.Welch, Coombs 2 3 JF420294 JF420403 KC421329 KC955795 & McGlynn JF420506 Acacia dempsteri F.Muell.
    [Show full text]
  • House Bill No. 1176
    FIRST REGULAR SESSION HOUSE BILL NO. 1176 101ST GENERAL ASSEMBLY INTRODUCED BY REPRESENTATIVE DAVIS. 2248H.01I DANA RADEMAN MILLER, Chief Clerk AN ACT To repeal sections 191.480 and 579.015, RSMo, and to enact in lieu thereof two new sections relating to investigational drugs. Be it enacted by the General Assembly of the state of Missouri, as follows: Section A. Sections 191.480 and 579.015, RSMo, are repealed and two new sections 2 enacted in lieu thereof, to be known as sections 191.480 and 579.015, to read as follows: 191.480. 1. For purposes of this section, the following terms shall mean: 2 (1) "Eligible patient", a person who meets all of the following: 3 (a) Has a debilitating, life-threatening, or terminal illness; 4 (b) Has considered all other treatment options currently approved by the United States 5 Food and Drug Administration and all relevant clinical trials conducted in this state; 6 (c) Has received a prescription or recommendation from the person's physician for an 7 investigational drug, biological product, or device; 8 (d) Has given written informed consent which shall be at least as comprehensive as the 9 consent used in clinical trials for the use of the investigational drug, biological product, or device 10 or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or 11 legal guardian has given written informed consent on the patient's behalf; and 12 (e) Has documentation from the person's physician that the person has met the 13 requirements of this subdivision; 14 (2) "Investigational drug, biological product, or device", a drug, biological product, or 15 device, any of which are used to treat the patient's debilitating, life-threatening, or terminal 16 illness, that has successfully completed phase one of a clinical trial but has not been approved EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law.
    [Show full text]
  • The Genus Anadenanthera in Amerindian Cultures
    THE GENUS ANADENANTHERA IN AMERINDIAN CULTURES BY SIRI VON REIS ALTSCHUL, PH .D. RESEARCH FELLOW BOTANICAL MUSEUM HARVARD UNIVERSITY CAMBRIDGE, MASSACHUSETTS 1972 This monograph is dedicated in affectionate memory to the late DANIEL HERBERT EFRON, PH.D., M.D. 1913-1972 cherished friend of the author and of the Botanical Museum, a true scientist devoted to the interdisciplinary approach in the advancement of knowledge. A/""'f""'<J liz {i>U<// t~ },~u 0<<J4 ~ If;. r:J~ ~ //"'~uI ~ ()< d~ ~ !dtd't;:..1 "./.u.L .A Vdl0 If;;: ~ '" OU'''-k4 :/"­ tu-d ''''''"-''t2.. ?,,".jd,~ jft I;ft'- ?_rl; A~~ ~r'4tft,t -5 " q,.,<,4 ~~ l' #- /""/) -/~ "1'Ii;. ,1""", "/'/1'1",, I X C"'-r'fttt. #) (../..d ~;, . W,( ~ ~ f;r"'" y it;.,,J 11/" Y 4J.. %~~ l{jr~ t> ~~ ~txh '1'ix r 4 6~" c/<'T'''(''-;{' rn« ?.d ~;;1';;/ a-.d txZ-~ ~ ;o/~ <A.H-iz "" ~".,/( 1-/X< "..< ,:" -.... ~ ~ . JJlr-0? on .­ .it-(,0.1' r 4 -11<.1.- aw./{') -:JL. P7t;;"j~;1 S .d-At ;0~/lAQ<..t ,ti~?,f,.... vj "7rU<-'- ~I""" =iiR-I1;M~ a....k«<-l, ¢- f!!) d..;.:~ M ~ ~y£/1 ~/.u..-... It'--, "" # :Z:-,k. "i ~ "d/~ efL<.<~/ ,w 1'#,') /';~~;d-t a;.. tlArl-<7'" I .Ii;'~.1 (1(-;.,} >Lc -(l"7C),.,..,;.. :.... ,,:/ ~ /-V,~ , ,1" # (i F'"' l' fJ~~A- (.tG- ~/~ Z:--7Co- ,,:. ,L7r= f,-, , ~t) ahd-p;: fJ~ / tr>d .4 ~f- $. b".,,1 ~/. ~ pd. 1'7'-· X ~-t;;;;.,~;z jM ~0Y:tJ;; ~ """.,4? br;K,' ./.n.u" ~ 7r .".,.~,j~ ;;f;tT ~ ..4'./ ;pf,., tJd~ M_~ (./I<'/~.'. IU. et. c./,. ~L.y !f-t.<H>:t;.tu ~ ~,:,-,p., .....:.
    [Show full text]
  • 5-Meo-DMT) in a Journal of Psychedelic Studies Naturalistic Setting
    A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N- dimethyltryptamine (5-MeO-DMT) in a Journal of Psychedelic Studies naturalistic setting 4 (2020) 2, 104–113 1p 2 DOI: MALIN V. UTHAUG , R. LANCELOTTA , 3 4,5 10.1556/2054.2020.00123 A. M. ORTIZ BERNAL , A. K. DAVIS and p © 2020 The Author(s) JOHANNES G. RAMAEKERS1 1 Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, The Netherlands 2 ORIGINAL ARTICLE Innate Path, Lakewood, CO, USA 3 School of Human Ecology, Human Development and Family Studies, University of Wisconsin, Madison, WI, USA 4 College of Social Work, The Ohio State University, Columbus, 43210, OH, USA 5 Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, 21224, MD, USA Received: November 18, 2019 • Accepted: December 22, 2019 Published online: March 26, 2020 ABSTRACT Background: Previous research suggests a therapeutic potential of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). However, online anecdotal reports have described a phenomenon following cessation of the acute effects of 5-MeO-DMT use which has been termed reactivation (i.e., re-experiencing [“flashback”]). To date, no research has investigated whether different routes of administration may confer different reactivation rates, effects and experiences. Aims: We aimed to assess whether intramuscular injection (IM) and vaporization of 5-MeO-DMT conferred different reactivation rates, changes in satisfaction with life as well as ratings of the experience with ego dissolution and the mystical. Methods: Using internet-based advertisements, 27 respondents (Mage = 32.
    [Show full text]
  • Long-Lasting Analgesic Effect of the Psychedelic Drug Changa: a Case Report
    CASE REPORT Journal of Psychedelic Studies 3(1), pp. 7–13 (2019) DOI: 10.1556/2054.2019.001 First published online February 12, 2019 Long-lasting analgesic effect of the psychedelic drug changa: A case report GENÍS ONA1* and SEBASTIÁN TRONCOSO2 1Department of Anthropology, Philosophy and Social Work, Universitat Rovira i Virgili, Tarragona, Spain 2Independent Researcher (Received: August 23, 2018; accepted: January 8, 2019) Background and aims: Pain is the most prevalent symptom of a health condition, and it is inappropriately treated in many cases. Here, we present a case report in which we observe a long-lasting analgesic effect produced by changa,a psychedelic drug that contains the psychoactive N,N-dimethyltryptamine and ground seeds of Peganum harmala, which are rich in β-carbolines. Methods: We describe the case and offer a brief review of supportive findings. Results: A long-lasting analgesic effect after the use of changa was reported. Possible analgesic mechanisms are discussed. We suggest that both pharmacological and non-pharmacological factors could be involved. Conclusion: These findings offer preliminary evidence of the analgesic effect of changa, but due to its complex pharmacological actions, involving many neurotransmitter systems, further research is needed in order to establish the specific mechanisms at work. Keywords: analgesic, pain, psychedelic, psychoactive, DMT, β-carboline alkaloids INTRODUCTION effects of ayahuasca usually last between 3 and 5 hr (McKenna & Riba, 2015), but the effects of smoked changa – The treatment of pain is one of the most significant chal- last about 15 30 min (Ott, 1994). lenges in the history of medicine. At present, there are still many challenges that hamper pain’s appropriate treatment, as recently stated by American Pain Society (Gereau et al., CASE DESCRIPTION 2014).
    [Show full text]
  • EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011)
    EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011) 912 final COMMISSION STAFF WORKING PAPER on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Accompanying the document REPORT FROM THE COMMISSION on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances {COM(2011) 430 final} EN EN TABLE OF CONTENTS 1. Introduction...................................................................................................................3 2. Methodology.................................................................................................................4 3. Key findings from the 2002 evaluation of the Joint Action on synthetic drugs ...........5 4. Overview of notifications, types of substances and trends at EU level 2005-2010......7 5. Other EU legislation relevant for the regulation of new psychoactive substances.....12 6. Functioning of the Council Decision on new psychoactive substances .....................16 7. Findings of the survey among Member States............................................................17 7.1. Assessment of the Council Decision ..........................................................................17 7.2. Stages in the functioning of the Council Decision .....................................................18 7.3. National responses to new psychoactive substances ..................................................20
    [Show full text]
  • Soma and Haoma: Ayahuasca Analogues from the Late Bronze Age
    ORIGINAL ARTICLE Journal of Psychedelic Studies 3(2), pp. 104–116 (2019) DOI: 10.1556/2054.2019.013 First published online July 25, 2019 Soma and Haoma: Ayahuasca analogues from the Late Bronze Age MATTHEW CLARK* School of Oriental and African Studies (SOAS), Department of Languages, Cultures and Linguistics, University of London, London, UK (Received: October 19, 2018; accepted: March 14, 2019) In this article, the origins of the cult of the ritual drink known as soma/haoma are explored. Various shortcomings of the main botanical candidates that have so far been proposed for this so-called “nectar of immortality” are assessed. Attention is brought to a variety of plants identified as soma/haoma in ancient Asian literature. Some of these plants are included in complex formulas and are sources of dimethyl tryptamine, monoamine oxidase inhibitors, and other psychedelic substances. It is suggested that through trial and error the same kinds of formulas that are used to make ayahuasca in South America were developed in antiquity in Central Asia and that the knowledge of the psychoactive properties of certain plants spreads through migrants from Central Asia to Persia and India. This article summarizes the main arguments for the botanical identity of soma/haoma, which is presented in my book, The Tawny One: Soma, Haoma and Ayahuasca (Muswell Hill Press, London/New York). However, in this article, all the topics dealt with in that publication, such as the possible ingredients of the potion used in Greek mystery rites, an extensive discussion of cannabis, or criteria that we might use to demarcate non-ordinary states of consciousness, have not been elaborated.
    [Show full text]
  • Review of Psilocybin/Psilocin Pharmacology Isaac Dehart
    Review of Psilocybin/Psilocin Pharmacology Isaac DeHart Introduction Psilocybin (PY, 4-phosphoryloxy-N,N-dimethyltryptamine or O-phosphoryl-4-hydroxy- N,N-dimethyltryptamine) (Figure 1, 1) is an indolamine (Figure 1, 2), and the primary ingredient in magic mushrooms. It has been implicated as a treatment for a number of psychological ailments including depression, general anxiety disorder, various addictions, obsessive- compulsive disorder, and post-traumatic stress disorder.1–4 Because of the drug’s re-emerging relevance in clinical applications, and because of its distinctive and informative effects on brain function, it is important to understand the pharmacology and general chemistry underlying its metabolism. Psilocybin is a prodrug of psilocin Magic mushrooms, the natural source of psilocybin may refer to several different hallucination-causing fungi, but the most potent of these are found in the genus Psilocybe. When ingested, magic mushrooms cause “trips,” wherein a user experiences euphoria, colorful hallucinations, and changes in perception, cognition and mood. In the case of “bad trips,” a user may experience states of intense panic or paranoia.5,6 More generally, these trips are sometimes described in terms of psychotic states, and behavioral studies involving psilocybin have demonstrated similarities between the effects of psilocybin and schizophrenia both in subjective experience and in physiological response.7 While psilocybin is more widely known as the cause behind these effects, it is referred to by researchers as a prodrug,
    [Show full text]
  • Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics
    TESI DOCTORAL HUMAN PHARMACOLOGY OF AYAHUASCA JORDI RIBA Barcelona, 2003 Director de la Tesi: DR. MANEL JOSEP BARBANOJ RODRÍGUEZ A la Núria, el Marc i l’Emma. No pasaremos en silencio una de las cosas que á nuestro modo de ver llamará la atención... toman un bejuco llamado Ayahuasca (bejuco de muerto ó almas) del cual hacen un lijero cocimiento...esta bebida es narcótica, como debe suponerse, i á pocos momentos empieza a producir los mas raros fenómenos...Yo, por mí, sé decir que cuando he tomado el Ayahuasca he sentido rodeos de cabeza, luego un viaje aéreo en el que recuerdo percibia las prespectivas mas deliciosas, grandes ciudades, elevadas torres, hermosos parques i otros objetos bellísimos; luego me figuraba abandonado en un bosque i acometido de algunas fieras, de las que me defendia; en seguida tenia sensación fuerte de sueño del cual recordaba con dolor i pesadez de cabeza, i algunas veces mal estar general. Manuel Villavicencio Geografía de la República del Ecuador (1858) Das, was den Indianer den “Aya-huasca-Trank” lieben macht, sind, abgesehen von den Traumgesichten, die auf sein persönliches Glück Bezug habenden Bilder, die sein inneres Auge während des narkotischen Zustandes schaut. Louis Lewin Phantastica (1927) Agraïments La present tesi doctoral constitueix la fase final d’una idea nascuda ara fa gairebé nou anys. El fet que aquest treball sobre la farmacologia humana de l’ayahuasca hagi estat una realitat es deu fonamentalment al suport constant del seu director, el Manel Barbanoj. Voldria expressar-li la meva gratitud pel seu recolzament entusiàstic d’aquest projecte, molt allunyat, per la natura del fàrmac objecte d’estudi, dels que fins al moment s’havien dut a terme a l’Àrea d’Investigació Farmacològica de l’Hospital de Sant Pau.
    [Show full text]
  • Psilocybin Mushrooms Fact Sheet
    Psilocybin Mushrooms Fact Sheet January 2017 What are psilocybin, or “magic,” mushrooms? For the next two decades thousands of doses of psilocybin were administered in clinical experiments. Psilocybin is the main ingredient found in several types Psychiatrists, scientists and mental health of psychoactive mushrooms, making it perhaps the professionals considered psychedelics like psilocybin i best-known naturally-occurring psychedelic drug. to be promising treatments as an aid to therapy for a Although psilocybin is considered active at doses broad range of psychiatric diagnoses, including around 3-4 mg, a common dose used in clinical alcoholism, schizophrenia, autism spectrum disorders, ii,iii,iv research settings ranges from 14-30 mg. Its obsessive-compulsive disorder, and depression.xiii effects on the brain are attributed to its active Many more people were also introduced to psilocybin metabolite, psilocin. Psilocybin is most commonly mushrooms and other psychedelics as part of various found in wild or homegrown mushrooms and sold religious or spiritual practices, for mental and either fresh or dried. The most popular species of emotional exploration, or to enhance wellness and psilocybin mushrooms is Psilocybe cubensis, which is creativity.xiv usually taken orally either by eating dried caps and stems or steeped in hot water and drunk as a tea, with Despite this long history and ongoing research into its v a common dose around 1-2.5 grams. therapeutic and medical benefits,xv since 1970 psilocybin and psilocin have been listed in Schedule I of the Controlled Substances Act, the most heavily Scientists and mental health professionals criminalized category for drugs considered to have a consider psychedelics like psilocybin to be “high potential for abuse” and no currently accepted promising treatments as an aid to therapy for a medical use – though when it comes to psilocybin broad range of psychiatric diagnoses.
    [Show full text]